PMID- 36144196
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220928
IS  - 2218-1989 (Print)
IS  - 2218-1989 (Electronic)
IS  - 2218-1989 (Linking)
VI  - 12
IP  - 9
DP  - 2022 Aug 25
TI  - Metabolic Profiling of Jasminum grandiflorum L. Flowers and Protective Role 
      against Cisplatin-Induced Nephrotoxicity: Network Pharmacology and In Vivo 
      Validation.
LID - 10.3390/metabo12090792 [doi]
LID - 792
AB  - Cisplatin (CP) is a powerful chemotherapeutic agent; however, its therapeutic use 
      is restricted due to its nephrotoxicity. In this work, we profiled the 
      phytoconstituents of Jasminum grandiflorum flower extract (JGF) using LC-MS/MS 
      and explored the possible molecular mechanisms against acute renal failure 
      through pharmacological network analysis. Furthermore, the possible molecular 
      mechanisms of JGF against acute renal failure were verified in an in vivo 
      nephrotoxicity model caused by cisplatin. LC-MS analysis furnished 26 secondary 
      metabolites. Altogether, there were 112 total hit targets for the identified 
      metabolites, among which 55 were potential consensus targets related to 
      nephrotoxicity based on the network pharmacology approach. Upon narrowing the 
      scope to acute renal failure, using the DisGeNET database, only 30 potential 
      targets were determined. The computational pathway analysis illustrated that JGF 
      might inhibit renal failure through PI3K-Akt, MAPK signaling pathway, and EGFR 
      tyrosine kinase inhibitor resistance. This study was confirmed by in vivo 
      experiment in which kidneys were collected for histopathology and gene expression 
      of mitogen-activated protein kinase 4 (MKK4), MKK7, I-CAM 1, IL-6, and TNF 
      receptor-associated factor 2 (TRAF2). The animal-administered cisplatin exhibited 
      a substantial rise in the expression levels of the MMK4, MKK7, I CAM 1, and TRFA2 
      genes compared to the control group. To summarize, J. grandiflorum could be a 
      potential source for new reno-protective agents. Further experiments are needed 
      to confirm the obtained activities and determine the therapeutic dose and time.
FAU - Alqahtani, Moneerah J
AU  - Alqahtani MJ
AUID- ORCID: 0000-0003-3013-1354
AD  - Department of Pharmacognosy, College of Pharmacy, King Saud University, P.O. Box 
      2457, Riyadh 11451, Saudi Arabia.
FAU - Mostafa, Sally A
AU  - Mostafa SA
AD  - Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, 
      Mansoura University, Mansoura 35511, Egypt.
FAU - Hussein, Ismail A
AU  - Hussein IA
AUID- ORCID: 0000-0001-6033-7359
AD  - Department of Pharmacognosy and Medicinal Plants, Faculty of Pharmacy (Boys), 
      Al-Azhar University, Cairo 11884, Egypt.
FAU - Elhawary, Seham
AU  - Elhawary S
AD  - Department of Pharmacognosy, Faculty of Pharmacy, Cairo University, Cairo 11562, 
      Egypt.
FAU - Mokhtar, Fatma A
AU  - Mokhtar FA
AD  - Department of Pharmacognosy, Faculty of Pharmacy, ALSalam University, Al 
      Gharbiya, Kafr El Zayat 31616, Egypt.
FAU - Albogami, Sarah
AU  - Albogami S
AUID- ORCID: 0000-0003-0774-5550
AD  - Department of Biotechnology, College of Science, Taif University, P.O. Box 11099, 
      Taif 21944, Saudi Arabia.
FAU - Tomczyk, Michal
AU  - Tomczyk M
AUID- ORCID: 0000-0002-4063-1048
AD  - Department of Pharmacognosy, Medical University of Bialystok, ul. Mickiewicza 2a, 
      15-230 Bialystok, Poland.
FAU - Batiha, Gaber El-Saber
AU  - Batiha GE
AUID- ORCID: 0000-0002-7817-425X
AD  - Department of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, 
      Damanhour University, Damanhour 22511, Egypt.
FAU - Negm, Walaa A
AU  - Negm WA
AUID- ORCID: 0000-0003-0463-8047
AD  - Department of Pharmacognosy, Faculty of Pharmacy, Tanta University, Tanta 31527, 
      Egypt.
LA  - eng
PT  - Journal Article
DEP - 20220825
PL  - Switzerland
TA  - Metabolites
JT  - Metabolites
JID - 101578790
PMC - PMC9502427
OTO - NOTNLM
OT  - LC-MS/MS
OT  - MAPK pathway
OT  - enrichment analysis
OT  - gene expression
OT  - network pharmacology
OT  - protein-protein interaction
COIS- The authors declare no conflict of interest.
EDAT- 2022/09/24 06:00
MHDA- 2022/09/24 06:01
PMCR- 2022/08/25
CRDT- 2022/09/23 01:34
PHST- 2022/07/27 00:00 [received]
PHST- 2022/08/15 00:00 [revised]
PHST- 2022/08/22 00:00 [accepted]
PHST- 2022/09/23 01:34 [entrez]
PHST- 2022/09/24 06:00 [pubmed]
PHST- 2022/09/24 06:01 [medline]
PHST- 2022/08/25 00:00 [pmc-release]
AID - metabo12090792 [pii]
AID - metabolites-12-00792 [pii]
AID - 10.3390/metabo12090792 [doi]
PST - epublish
SO  - Metabolites. 2022 Aug 25;12(9):792. doi: 10.3390/metabo12090792.